Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Newron Pharmaceuticals
Newron Pharmaceuticals
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Safinamide to be made available in Asia for Parkinson's
Meiji Seika and Eisai enter into a collaboration for the development and commercialisation of safinamide in Parkinson’s disease for Japan and Asia
FDA approves Xadago for Parkinson’s patients
Xadago (safinamide) is first NCE approved in the USA for PD patients with motor fluctuations in a decade
Pharmaceutical
Newron starts operations in New Jersey, US
Two senior executives join the company and will be located in Morristown, New Jersey
Regulatory
Parkinson’s disease – safinamide
The effectiveness of dopamine agonist drugs to treat Parkinson\'s disease decreases over time as more and more dopamine-producing cells die
Research & Development
Newron receives €2.5m grant from Wellcome Trust
To fund clinical trial for amyotrophic lateral sclerosis (ALS)
Finance
Newron to acquire NeuroNova for €15.4m
Gains two Phase II compounds for progressive neurogenerative diseases
Research & Development
Newron and Zambon enter into a new €5m agreement for safinamide
Zambon will make a total investment in Newron of €20m
Subscribe now